Search hospitals > Tennessee > Nashville
Tennessee Oncology
Claim this profileNashville, Tennessee 37203
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Solid Tumors
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
246 reported clinical trials
14 medical researchers
Summary
Tennessee Oncology is a medical facility located in Nashville, Tennessee. This center is recognized for care of Cancer, Breast Cancer, Solid Tumors, Lung Cancer, Non-Small Cell Lung Cancer and other specialties. Tennessee Oncology is involved with conducting 246 clinical trials across 205 conditions. There are 14 research doctors associated with this hospital, such as Melissa Johnson, MD, Erika P Hamilton, Meredith A McKean, and David R. Spigel, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
KRAS positive
2Breast Cancer
Global LeaderStage IV
HER2 negative
Stage III
Top PIs
Melissa Johnson, MDSarah Cannon Research Institute6 years of reported clinical research
Expert in Non-Small Cell Lung Cancer
Expert in Lung Cancer
66 reported clinical trials
94 drugs studied
Erika P HamiltonSarah Cannon Research Institute5 years of reported clinical research
Expert in Breast Cancer
Expert in Ovarian Cancer
55 reported clinical trials
77 drugs studied
Meredith A McKeanSarah Cannon Research Institute1 year of reported clinical research
Expert in Cancer
Expert in Solid Tumors
35 reported clinical trials
67 drugs studied
David R. Spigel, MDTennessee Oncology4 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
29 reported clinical trials
54 drugs studied
Clinical Trials running at Tennessee Oncology
Cancer
Multiple Myeloma
Non-Small Cell Lung Cancer
Breast Cancer
Lymphoma
Ovarian Cancer
Solid Tumors
Lung Cancer
Chronic Lymphocytic Leukemia
Plasma Cell Neoplasm
INCB0123667
for Solid Tumors
This trial is testing a new drug called INCB123667 to see if it can help treat advanced or spreading cancers. It aims to find out how safe and effective the drug is, and how the body processes it. The study focuses on patients whose cancers are advanced or have spread.
Recruiting1 award Phase 1
AU-007
for Advanced Cancer
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w). Once the recommended phase 2 dose (RP2D) of AU-007 plus aldesleukin was determined, (AU-007 Q2w plus a single loading dose of aldesleukin), AU-007 plus aldesleukin is also being administered with avelumab or nivolumab.
Recruiting1 award Phase 1 & 28 criteria
NX-2127
for B-cell Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.
Recruiting1 award Phase 111 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Tennessee Oncology?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.